← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Xylyx Bio, Inc.
Brooklyn, NY
$6,759,416
Total funding
6
Grants
Funding over time
peak $3.2M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,759,416 · 6
By mechanism
R44$6,255,874 · 4
R43$503,542 · 2
Investigators at Xylyx Bio, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation$1,266,937
R44 · FY2025 · HL
Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development$967,715
R44 · FY2025 · DK
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development$966,420
R44 · FY2025 · CA
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$961,355
R44 · FY2023 · HL
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$950,532
R44 · FY2022 · HL
Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development$370,020
R44 · FY2024 · DK
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$297,924
R44 · FY2021 · HL
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development$295,604
R44 · FY2024 · CA
Fibrotic lung extracellular matrix cell culture substrate to improve predictive in vitro models of pulmonary fibrosis for accelerating drug development towards more effective treatment options$224,566
R43 · FY2018 · HL
Biomimetic lung sealant to rapidly heal pulmonary air leaks, decrease recovery time, and reduce associated costs to the healthcare system,$224,101
R43 · FY2020 · HL
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$109,343
R44 · FY2023 · HL
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$70,024
R44 · FY2023 · HL
Native cell specific microenvironments for improved cell culture$54,875
R43 · FY2019 · HL